Wockhardt Limited operates in the Pharmaceutical preparations sector. Wockhardt Limited (Wockhardt) is a pharmaceutical and biotechnology company engaged in pharmaceutical business. The Company together with its subsidiaries is primarily engaged in the business of manufacture and marketing of pharmaceutical products. The Company has twelve manufacturing locations and there are five locations where research and development activities are carried out. Wockhardt's output includes steriles (injectables), biopharmaceuticals, orals (tablets and liquids) and topicals (creams and ointments). Wockhardt's three principal products/services include Spasmoproxyvon, Proxyvon and Methycobal. Wockhardt's has also launched three products in the Indian market, which include Biovac-B (hepatitis B vaccine), Wepox (erythropoietin) and Wosulin (recombinant insulin). During the fiscal year ended March 31, 2011 (fiscal 2011), a total of 43 new products were launched in India. Wockhardt is a subsidiary of Khorakiwala Holdings and Investments Private Limited. In our complete report available for purchase the company is compared to: Piramal Healthcare Limited, Aurobindo Pharma Ltd and Cadila Healthcare Ltd.